Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105.

Tomotaka Suzuki Dai MaruyamaRyunosuke MachidaTomoko KataokaNoriyasu FukushimaNobuyuki TakayamaRie OhbaKen OmachiYoshitaka ImaizumiMasahito TokunagaHiroo KatsuyaIsao YoshidaKazutaka SunamiMitsutoshi KurosawaNobuko KubotaHiroaki MorimotoMiki KobayashiKazuhito YamamotoYoshihiro KameokaYoshitoyo KagamiTakayuki TabayashiMasaki MarutaTsutomu KobayashiShinsuke IidaHirokazu Nagai

Published in: Hematological oncology (2022)

Keyphrases

multiple myeloma
high dose
cross sectional
phase iii
randomized controlled trial
clinical trial
low dose
newly diagnosed
open label